NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq:XBIT) and certain of its present and former officers in the United District Court for the Western District of Texas on behalf of a class consisting of all persons or entities who purchased XBiotech securities between April 15, 2015 through November 23, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (i) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (ii) the data from 72 patients of the Phase III Study was compromised; (iii) XBiotech did not adequately sample patients to accommodate data loss; (iv) as a result of not properly sampling patients for the Phase III Study, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome; and (v) as a result of the foregoing, Defendants’ statements about its business, operations, and prospects, including statements about the Phase III Study and clinical development of Xilonix, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 



